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Public–private partnerships (PPPs) have been increasingly used to spur and facilitate 
innovation in a number of fields. In healthcare, the purpose of using a PPP is com-
monly to develop and/or provide vaccines and drugs against communicable diseases, 
mainly in developing or underdeveloped countries. With the advancement of technology 
and of the area of genomics, these partnerships also focus on large-scale genomic 
research projects that aim to advance the understanding of diseases that have a genetic 
component and to develop personalized treatments. This new focus has created new 
forms of PPPs that involve information technology companies, which provide computing 
infrastructure and services to store, analyze, and share the massive amounts of data 
genomic-related projects produce. In this article, we explore models of PPPs proposed 
to handle, protect, and share the genomic data collected and to further develop 
genomic-based medical products. We also identify the reasons that make these models 
suitable and the challenges they have yet to overcome. To achieve this, we describe 
the details and complexities of MSSNG, International Cancer Genome Consortium, and 
100,000 Genomes Project, the three PPPs that focus on large-scale genomic research 
to better understand the genetic components of autism, cancer, rare diseases, and 
infectious diseases with the intention to find appropriate treatments. Organized as PPP 
and employing cloud-computing services, the three projects have advanced quickly and 
are likely to be important sources of research and development for future personalized 
medicine. However, there still are unresolved matters relating to conflicts of interest, 
commercialization, and data control. Learning from the challenges encountered by past 
PPPs allowed us to establish that developing guidelines to adequately manage personal 
health information stored in clouds and ensuring the protection of data integrity and 
privacy would be critical steps in the development of future PPPs.
Keywords: public–private partnerships, cloud computing, genomic research, large-scale projects, MSSNG, iCGC, 
1000 Genomes Project
iNTRODUCTiON
Public–private partnerships (PPPs) have been increasingly used to spur and facilitate innovation in 
a number of fields. Healthcare is one of them. Some examples include the PATH Malaria Vaccine 
Initiative, the Drugs for Neglected Diseases Initiative, the TB Alliance, and the International AIDS 
Vaccine Initiative. These partnerships usually involve a health authority, public hospitals or research 
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centers, and private companies, usually pharmaceuticals. The 
purpose is commonly to develop and/or provide vaccines and 
drugs against communicable diseases, mainly in developing or 
underdeveloped countries (1). With the advancement of tech-
nology and of the area of genomics, these partnerships started 
focusing on genomic research projects that aim to advance the 
understanding of diseases that have a genetic component and 
to develop personalized treatments. This new focus has brought 
about other forms of PPPs. These new forms of PPPs involve 
information technology (IT) companies, which provide comput-
ing infrastructure and services to store, analyze, and share the 
massive amounts of data genomic-related projects produce.
This article explores models of PPPs proposed to handle, 
protect, and share the genomic data collected and to further 
develop genomic-based medical products. It also identifies 
the reasons that make the model suitable for these purposes 
and the challenges it has yet to overcome. To achieve this, 
the article describes the details and complexities of MSSNG, 
International Cancer Genome Consortium (ICGC), and 
100,000 Genomes Project (100,000 GP), the three PPPs that 
focus on large-scale genomic research to better understand 
the genetic components of autism, cancer, rare diseases, and 
infectious diseases with the intention to find appropriate 
treatments. All the three projects require cloud-computing 
services (CCSs) to store, process, and share the massive 
amounts of genomic and health data that they collect. Both 
MSSNG and ICGC partnered with a commercial IT company 
that provides public CCSs. The 100,000 GP has a private cloud 
and partnered with private companies that do the sequencing 
of the DNA samples and that will develop diagnostic tools and 
treatments.
Our analysis compares these three genomic research projects, 
two of which (MSSNG and ICGC) include a well-established 
private IT company for the provision of CCSs as partners. We 
identify core elements about their organization, their goals, 
and current status and progress. The 100,000 GP has in-house 
(private) CCSs and partnered with private companies for other 
purposes [sequencing and interpretation assistance and transla-
tional research and development (R&D)]. This variation allows 
us to determine whether there is a difference between having a 
private specialized company handling the storage and sharing of 
genomic data or having in-house CCSs.
The sources we used for the description and analysis of the 
projects were the projects’ websites, documentation, and press 
releases without including internal private agreements with 
the companies that were not made public. Relying only on 
public documents, however, prevents us from learning about 
undisclosed challenges that the projects may encounter, their 
approaches to solve them, as well as private negotiations between 
the public and the private parties, all of which may limit our 
analysis. The sources we used for the context were peer-reviewed 
articles obtained from Google scholar using key terms such as 
“cloud-computing” and “public-private partnerships” alone 
and “cloud-computing” or “public-private partnerships” AND 
“health research,” “genomic research” or “medical genetics.” We 
also consulted Canadian, American, and British governmental 
websites and policies.
The article is organized into three sections. The first section 
presents the basic concepts of PPPs in the area of healthcare. 
This section intends to provide a general context on the char-
acteristics, uses, stakeholders, benefits, and challenges of PPPs. 
The second section focuses on the three large-scale genomic 
research projects that use a model of PPPs and CCSs to reach 
their goals. It starts with basic concepts of cloud computing 
including characteristics, models of service, deployment models, 
and stakeholders and uses in healthcare. It then focuses on each 
of the three genomic research projects. For each project, we 
describe the purpose, current status, parties involved and roles, 
data location, conditions of elasticity in terms of costs and space, 
extent of control that the leading organizations of the project 
have over the data stored, access conditions, and confidentiality 
and privacy mechanisms. The third section discusses the lessons 
learned from all the three projects including the benefits that the 
projects have found in using a PPP model as well as the chal-
lenges that they still face.
CONTeXT
PPPs in Health-Related and Genomic 
Research
In medical research (e.g., genomic, pharmaceutical, clinical, etc.), 
the development of innovative results and products requires a 
constant targeting of new diseases or conditions to better under-
stand the causes or factors associated with the disease, find and 
optimize new drugs and treatments, and address current safety, 
efficacy, and validation concerns. This challenging, complex, and 
constantly changing environment has encouraged parties from 
the public and the private sectors to intensify their collaboration 
(2). One common model of collaboration is that of a PPP with 
technological features that involves the use of CCSs.
A PPP is an agreement between the public and the private sec-
tors to collaborate with each other by sharing objectives, resources, 
risks, and responsibilities (3). The partnership can be national or 
international, depending on its partners. The purpose of a PPP in 
the context of innovation is to jointly tackle the difficulties of the 
different stages of the innovation and translation processes and to 
make those processes more efficient. This purpose is based on the 
acknowledgment that the innovation and translation processes 
are too diverse, burdensome, and lengthy for either to take on 
alone (2–4).
Public–private partnerships have become a very important 
and prolific model to spur innovation, strengthen businesses, 
and more efficiently build and maintain public infrastructure. For 
instance, they have been used in projects to build and maintain 
roads, bridges, tunnels, railroads, airports, schools, and hospitals. 
They have also been used to build and operate prisons and to 
provide the infrastructure to solve water supply problems (3–6). 
Research in many fields, including health, has also used PPPs 
(7). Particularly in the context of healthcare and health-related 
research, many PPPs are created to make the process of R&D 
of drugs, vaccines, diagnostic tests, and medical devices more 
efficient and effective, as well as to improve patients’ access to 
medical innovative products (2, 4, 8, 9).
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Different types of partnering may take place. Some include 
strategic innovation partnerships, consortia, joint research, 
crowdsourcing, outsourcing, licensing, incubator, and venture 
capital investments. The most common partners in PPPs in 
health-related research include public and private hospitals; 
public and private universities; non-for-profit organizations; 
patient organizations; small-, medium-, and big-size pharmaceu-
tical and biotechnology companies; and governmental agencies. 
Technological advances in IT (e.g., the power of hardware, soft-
ware, and mobility of devices), biomedicine, the different types 
of omics (e.g., genomics, proteomics, metabolimics, etc.), and the 
production of big data1 have attracted a new essential partner: IT 
companies (10).
Public–private partnerships are useful to improve access 
to health-care services as well as to spur R&D in the field (3). 
Since multiple partners will be able to combine their resources, 
infrastructure, and responsibilities, they may have the possibility 
to allocate their resources more efficiently and thereby use some 
of these resources to provide health-care services in a larger area. 
Furthermore, by combining resources, infrastructure, and skills 
from members of the public sector, PPPs may also help to focus on 
a specific condition that is endemic to a particular region where, 
because of the poor socio-economic conditions of its population, 
there is not a very profitable market and therefore potentially no 
interest from pharmaceutical companies. This focus may help to 
overcome situations of market failure and address diseases that 
would otherwise be neglected (3, 13). With respect to R&D, these 
partnerships could satisfy different needs, such as enabling access 
to new ideas or providing the perspectives of a broader com-
munity, overcoming complicated or extensive challenges such as 
regulatory approvals, transferring of knowledge or expertise, and 
establishing an earlier involvement with entrepreneurs (2).
Public–private partnerships allow the different partners to 
share resources that include economic funds, knowledge, exper-
tise, information (e.g., data and samples and patient base), and 
infrastructure. They also enable partners to share risks, responsi-
bilities, and networks of experts while accessing new ideas from 
a broader community. Sharing economic resources, risks, and 
responsibilities can alleviate the burdens inherent in the innova-
tion process making it less costly and faster. For instance, it can 
avoid or decrease the need for costly initial capital investments. 
Sharing expertise, ideas, information, and infrastructure can make 
the process more efficient, more fluid, and more interconnected. 
Overall, these benefits increase the value of the investment and 
infrastructure of all the partners as well as the value of the project 
the PPP was set for (2–4).
Public–private partnerships can also democratize the inno-
vation process, as more agents, and not only those with all the 
initial necessary resources, can participate. For instance, small- 
and medium-size companies could enter a PPP and participate 
in large-scale projects, which they would not be able to do, if 
they depended entirely on their own means and resources. This 
1 Big data can be defined as vast amounts of data with significant variety or 
heterogeneity that can be accessed and analyzed to reveal patterns, trends, and 
correlations [Dimitrov (10), p. 159; Costa (11), p. 433; Jordan (12), p. 5].
democratization could also benefit developing countries, as the 
governments and companies of these countries could be able to 
participate in projects that, because of the costly resources that 
they require, are more technologically and scientifically advanced 
and usually take place in developed countries. This could ulti-
mately promote the economic, scientific, and technological 
growth of these countries, as employment would be created, 
distribution of goods would be increased, and technological and 
scientific advancements would be transferred (14).
However, despite the abovementioned advantages of PPPs, 
there are certain difficulties that need to be considered and 
overcome. First, the parties entering the partnership may have 
unrealistic expectations about what the partnership is supposed 
to create. Second, the parties from the public sector tend to have 
objectives and interests that differ from those of the parties of 
the private sector. Third, the negotiation process to achieve 
these partnerships is complicated. This is even more serious in 
partnerships whose projects are caught in the middle of political 
debates or public opposition because of their focus or the subject 
matter of those projects. Fourth, there may be inadequate legal 
or regulatory frameworks, which could make the partnership 
more difficult to set or to maintain. Fifth, these partnerships 
need to be maintained, particularly in health-related research, as 
the processes of R&D in this field tend to be lengthy. These dif-
ficulties make the coordination and management of partnerships 
challenging (2–4, 7).
In order to address and even overcome some of the above-
mentioned difficulties, certain reforms have been suggested. For 
instance, it has been proposed that those who have the authority 
to make decisions in the project be involved in the R&D process 
from its inception. This would allow them to act in a timely man-
ner. Additionally, the coordination and decision-making process 
needs to be mindful of the specific field(s) associated with the 
project. Progress and deliverables need to be continuously moni-
tored in order to increase the chances of detecting any hurdle or 
setback that may arise. Work methods and agreements should be 
clarified. It is also recommended that political, legal, commercial, 
operational, environmental, and economic risks and responsibili-
ties be distributed among all the partners in a timely fashion. For 
this, they should be identified and distributed among the partners 
in accordance with the partners’ financial and technical capabili-
ties for management. In addition to all these recommendations, 
maintaining mutual confidence and trustworthiness throughout 
the project is one of the most important suggestions to ensure that 
the PPP succeeds (3, 7, 15).
Cloud Computing in Genomic Research
In health-related research, and particularly regarding genomic 
research, the involvement of IT companies in PPPs is essential. 
The development of devices to continuously collect data from 
patients created massive amounts of data. Furthermore, the 
advent of genomics and other omics fields and of technologies 
that accelerate the collection of data have also contributed to the 
production of massive, complex, and potentially helpful data 
(10, 12, 16). These data need to be stored, organized, analyzed, 
and made accessible to researchers and developers in order for 
them to discern patterns, associations, and trends for the better 
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understanding of diseases in order to create improved and cus-
tomized diagnostic tests, drugs, vaccines, and treatments (10, 11). 
These needs often create problems of interoperability among the 
different sources of the aforesaid data and platforms, high costs of 
infrastructures, and other necessary technological tools. Hence, 
trained personnel are required to manage, operate, and maintain 
the infrastructure as well as to be capable to analyze, process, and 
share the data (12, 17). In order to address these problems, CCS 
providers are desirable partners in genomic research partnerships 
(14–18).
Cloud computing is defined “as a model for enabling ubiq-
uitous, convenient, on-demand network access to a shared 
pool of configurable computing resources (e.g., networks, 
servers, storage, applications, and services) that can be rapidly 
provisioned and released with minimal management effort or 
service provider interaction” (19, 20). Based on this definition 
of the National Institute of Standards and Technology, CCSs are 
provided on demand (server time or storage), accessible through 
the use of standard mechanisms over a broad network, immersed 
in a resource pool serving multiple consumers, and elastic. The 
elasticity allows multi-tenancy (i.e., one single application can 
serve multiple users) (16, 20, 21).
Cloud-computing services can be deployed in a private cloud, 
a community cloud, a public (commercial) cloud, or in a hybrid 
cloud. A private cloud provides exclusive services to one single 
organization, and the infrastructure (data center) is owned, man-
aged, and operated either by that same organization that uses it or 
by a third party. A community cloud provides services to a spe-
cific group with a common interest, and the infrastructure may 
be owned, managed, and operated by one or more organizations 
in the group or a third party. A public cloud provides services to 
the general public, and the infrastructure is owned, managed, and 
operated by a company, an academic or governmental organiza-
tion, or a combination of both. A hybrid cloud is composed of 
two or more clouds that can be private, public, or community 
(15, 16, 18, 20, 22).
Cloud-computing services are offered in three models: 
infrastructure-as-a-service,2 platform-as-a-service,3 and soft-
ware-as-a-service4 (15, 16, 20, 22). Some authors also include 
mobile backend-as-a-service5 (21, 23). Four types of stakehold-
2 The IaaS provides storage, networks, and analytical/processing computing ser-
vices for application program interfaces (APIs) to migrate workloads and data to a 
virtual machine. In this case, users have a determined storage capacity, processing 
capability, and other resources that they can use to start, stop, access, and configure 
the virtual machine they have been assigned. They are allowed to install their own 
operating systems and applications on the infrastructure provided [Mell and Grace 
(20), p. 3; Dove et al. (15), p. 1272; Kuo (22), p. 2; Marston et al. (21), p. 178].
3 The PaaS hosts development tools that are made available via APIs, browsers, or 
software to develop and deploy software applications onto a cloud infrastructure 
[Mell and Grace (20), p. 2 and 3; Dove et al. (15), p. 1272; Kuo (22), p. 2; Marston 
et al. (21), p. 178].
4 The SaaS allows users to deliver software applications and run them on a cloud 
infrastructure. The applications are accessible from the users’ devices through 
the use of a web browser or a program interface, without the need to install the 
application in a particular computer [Mell and Grace (20), p. 2; Dove et al. (15), p. 
1273; Kuo (22), p. 2; Marston et al. (21), p. 178].
5 The MBaaS provides a way to link web applications and mobile applications to a 
cloud infrastructure.
ers are associated with CCSs in health-care fields. The first ones 
are end-users (also called consumers). They use the services on 
demand based on their own specific needs. End-users include 
physicians, medical staff, patients, medical researchers, and IT 
experts. Patients use CCSs for purposes of personal health-
care management. Medical researchers and staff use them for 
medical and genomic research. Finally, IT staff employs CCSs 
for the creation and implementation of cloud-based solutions 
(16). The second type of stakeholders refers to service providers 
(companies and organizations). They own, operate, maintain, 
and update the system and provide the service to the end-users. 
The enablers are the third type of stakeholders. Even though 
not essential, they sell products and services to facilitate the 
delivery and use of the CCSs. Finally, the regulators are in 
charge of providing guidelines, standards, and rules regarding 
the proper and ethical use of CCSs. These regulators can be 
national or international. Regulations can focus on privacy, 
security, liability, intellectual property, cross-border issues, 
access and transfer, governmental extent of monitoring and 
access, and forensics (21).
Cloud-computing services bring a number of benefits. 
For example, they allow companies and organizations to use 
computing resources (e.g., storage and analytical comput-
ing) as a utility on a pay-per-use basis. This condition results 
in costs reduction, as the infrastructure needed is “rented,” 
rather than having to invest in building and maintaining the 
infrastructure. These reduced costs allow any company or 
organization, including those that are small and medium sizes, 
to enter the research field, potentially also benefiting compa-
nies, organizations, and entities in developing countries. The 
latter could avoid costly investments while using and exploiting 
state-of-the-art computing processes. CCSs can rapidly and 
easily scale-up or scale-down on a need-to basis. This situation 
gives customers flexibility to add, expand, reduce, eliminate, or 
re-distribute their resources and services. Moreover, companies 
and organizations can hire on-demand self-services and decide 
the location of the server where their data will be stored. IT 
experts are responsible for maintaining the infrastructure, thus 
making the upkeep of the cloud easier. Customers can share 
resources and costs among themselves, allowing a more efficient 
use of resources and reduced costs and timelines. The use of 
CCSs can also increase productivity in the development of the 
projects undertaken by customers, given that multiple users 
can work simultaneously on the same data and collaborate 
without the need for constant software upgrades. Along with 
this efficient use of resources, CCSs also reduce the time that 
clinical and genomic research takes. Usually, these processes 
require researchers to download or upload data to their local 
computers in order to process, analyze, and obtain results. These 
results then need to be uploaded to repositories for publishing 
and sharing. Since cloud computing eliminates the need to 
download the data, the whole process is shortened. In addition, 
given that there is no need to build and maintain individual 
infrastructure each time a project requires computing services, 
the use of CCSs could be considered more environmentally 
friendly. Finally, even though there are still concerns about 
losing control over certain data, the centralization of the data, 
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the increased security-focused resources (e.g., encryption tools 
and techniques, firewalls, auditing capabilities, etc.), and the 
specialization of IT personnel that focuses on these matters are 
ways to increase the level of security (15, 21, 22, 24).
The most serious challenge with CCSs in healthcare is the 
perceived risk of possible loss of control of health data, jeopard-
izing the safety and security of data and patients’ privacy and 
confidentiality. A proposed solution is the use of controlled 
access, audit control, authentication, authorization mecha-
nisms, as well as transmission and storage security. Some of 
these tools include secure transmission protocols, special secu-
rity certificates, access control lists, electronic keys, and digital 
signatures. However, these measures may be inconvenient, 
particularly in emergency situations. The use of tools that allow 
the anonymity of data has also been suggested,6 but anonymiza-
tion prevents the return of health results. Data integrity may 
also be at stake due to hacker attacks, network failures, or poor 
management. Again, the use of controlled access, authentica-
tion, authorization, and transmission and storage security 
measures can also help to preserve data integrity. Ensuring that 
CCS providers have appropriate backups and retrieval meas-
ures in place can be also helpful. Another concern regarding 
the use of CCSs is reliability. Cloud-computing providers can 
suffer outages (e.g., Amazon’s outages in 2008, 2011, and 2012). 
They may also suspend certain services either temporarily or 
permanently (e.g., Google Health). CCS providers also have to 
ensure compliance with data privacy laws of the specific loca-
tions of the data centers where data are stored and transferred. 
Getting end-users to trust CCSs and providers, particularly 
with respect to data security and privacy, is perhaps the greatest 
challenge (15, 16, 22, 24).
Irrespective of these challenges, CCSs have been used in sev-
eral areas of healthcare: telemedicine/teleconsultation,7 medical 
imaging,8 public health and patient self-management,9 hospital 
6 An example of anonymity tools is the use of a biological PIN code that allows a 
donor to provide a sample without any identity data. In this case, the registration of 
the sample includes only the individual’s unique biological characteristics without 
enabling any link back to the donor [Dove et al. (15), p. 1271].
7 Cloud-computing services in telecommunication/teleconsultation allow actors in 
the area of healthcare (e.g., medical practitioners, specialists, clinicians, nurses, 
paramedics, etc.) to communicate and share data. An example of this case would 
be collecting, accessing, sharing, and analyzing the data of a particular patient 
from different hospitals or health-care providers (e.g., patient records and medical 
history). For instance, the Cloud Cardiology enables medical professionals to share 
ECGs simultaneously with members of the hospital and with other practitioners 
outside the hospital [Griebel et al. (16), p. 4].
8 Cloud-computing services are used in the area of medical imaging to store, share, 
and process images. An example of this type of images would be X-rays. For 
instance, Accenture Medical Imaging Solution is built to review X-rays, MRI, and 
CT scans [Griebel et al. (16), p. 7; Ahuja et al. (24), p. 15].
9 Cloud-computing services enable broad access to health data concerned with 
disease prevention, health promotion, and improvement of the population’s health. 
For instance, they may be used to store personal health and lifestyle data collected 
by mobile devices and extract patterns that would help prevent epidemics and 
improve the population’s health. They can also be used to monitor the progress 
of conditions such as post-traumatic disorder syndrome (Tele-PTSD Monitor) or 
to provide specialized training routines after receiving physiological data (iFit) 
[Griebel et al. (16), p. 8].
management and information systems,10 therapy,11 and second-
ary use of data (16). Genomic research in particular benefits 
from the secondary use of data. Since CCSs enable the storage 
of massive amounts of data and the use of complex computing 
processes at reduced costs, it is possible to simultaneously do 
clinical and genomic data analysis, text mining, and ongoing 
clinical research (16).
By enabling global access to clinical and genomic data and 
other resources, CCS providers unlock the value of big data, and 
particularly of genomic data. Global access to such data allows 
scientists, researchers, and developers to use data generated 
in different regions, from different patients, and with different 
techniques. It also allows researchers and developers from dif-
ferent backgrounds and multiple disciplines to work together 
simultaneously. This diversity enables them to better identify and 
understand patterns, variants, and correlations among the mul-
titude of factors that cause or prompt a disease so as to innovate 
and eventually provide accessible health-care services (14, 15). 
These advantages constitute the rationale for the involvement and 
uptake by research centers, academic institutions, and govern-
mental agencies in PPPs. Private companies have reasons as well 
for getting involved in CCSs and in PPPs in the area of genomic 
and medical research. The first reason is economic. Given the 
advantages posed to end-users, the demand for these services 
has greatly increased in the past and is expected to grow even 
more within the next few years. In 2014, the value of the cloud-
computing industry was expected to be $150 billion. Furthermore, 
companies providing public, community, and hybrid clouds are 
able to avoid the underutilization of their infrastructure and of 
their other resources. The third reason is that some companies are 
increasingly interested in contributing to improving the popula-
tion’s health (21).
Governmental policies and regulatory frameworks can help to 
create favorable conditions for the success of PPPs and the use of 
CCSs (3). The “Cloud First” policy in the U.S. is an example of a 
governmental policy that supports and encourages partnerships 
with new technology.12 Laws and policies that address issues of 
consent, privacy, and personal data applicable in the context of 
cloud computing can also facilitate the use of CCSs, as they can 
increase the trust of the general public, research institutions, 
and funding agencies on projects involving cloud-computing 
technology (3, 15, 27).
10 Cloud-computing services allow hospitals to digitalize health records, update 
clinical processes, and give access to medical staff at anytime and from anywhere. 
They can also provide faster and more accurate billing [Kuo (22), p. 4].
11 Cloud-computing services help to host and operate applications for planning, 
managing, and assessing therapeutic interventions. For instance, VirtuaLinac is 
a web application used to model radiation treatment components. iSMART is a 
cloud-computing web server that provides access to information on over 20,000 
compounds of traditional Chinese medicine that focuses on identifying compatible 
and derivative compounds that could be useful for drug research [Griebel et al. 
(16), p. 9; Chang et al. (25)].
12 The U.S. Cloud First policy was launched in February 2011. Its purpose was to 
encourage the governmental agencies to evaluate the possibility of implementing 
safe and secure cloud-computing options before making any investments in IT 
infrastructure. With this policy, the U.S. government was aiming to be more 
efficient, agile, and innovative (26).
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For example, in general terms, consent rules usually require that 
any use or disclosure of health information is previously author-
ized in writing by the individual to whom the information belongs. 
However, recent consent policies and projects have changed so as 
to adapt to and benefit from recent practices of democratization 
of access of data, by which many researchers from different centers 
share and analyze data. MSSNG is an example (14, 28, 29).
In the U.S., the Health Insurance Portability and Accountability 
Act (HIPAA) provides national standards for the protection of 
certain health/medical information (privacy rule) and for the 
protection of this information when it is held or transferred in 
electronic form (security rule). The main purpose of HIPAA is 
to allow covered entities13 to adopt new technologies in order to 
improve patients’ health while still protecting the privacy of indi-
viduals’ health information. The health information protected is 
“all individually identifiable health information14 held or trans-
mitted by a covered entity or its business associate,15 in any form 
or media, whether electronic, paper or oral.” CCS providers can 
be considered business associates. HIPAA can encourage the use 
of CCSs, as it allows the donors of genomic data to trust that risks 
to the safety of their data or to their privacy will be minimized16 
13 The term “covered entities” refers to any health plans, health-care clearinghouses, 
and any health-care provider who transmits health information in electronic form 
in connection with transactions for which the Secretary of HHS has adopted 
standard under HIPAA [US Department of Health and Human Services (28), p. 2].
14 Individually identifiable health information refers to “information that relates to 
the individual’s past, present, or future physical or mental health or condition, the 
provision of health care to the individual or the past, present or future payment for 
the provision of healthcare to the individual, and that identifies the individual or for 
which there is a reasonable basis to believe can be used to identify the individual.” 
[US Department of Health and Human Services (28), p. 4].
15 Business associate is defined as a person or organization, different from a member 
of a covered entity’s workforce that performs certain functions or activities or that 
provides certain services to a covered entity involving the use or disclosure of 
individually identifiable health information. Some of these activities include claims 
processing, data analysis, utilization review, and billing. The services are legal, 
actuarial, accounting, consulting, data aggregation, management, administrative, 
accreditation, or financial [US Department of Health and Human Services (28), p. 3].
16 Some of the rules stated by HIPAA to protect health information are the fol-
lowing. (1) That covered entities must have policies and procedures to maintain 
their workforce’s access and use of protected health information to the minimum 
amount reasonably necessary and in accordance with their specific roles. (2) That 
they must also have privacy practices. (3) That companies and organizations are 
prohibited from sharing personal health data to non-affiliated parties. (4) That the 
use or disclosure of an individual’s protected health information by a covered entity 
requires the written consent of such an individual or that such use or disclosure 
falls within the allowed or required uses or disclosures stated by the privacy rule. 
Required disclosures are those that have to be made to the individuals when they 
request access to their information and to HHS when an investigation, review, or 
enforcement action orders it. The allowed uses and disclosures are those made to 
the individual, those in association with treatment, payment and healthcare opera-
tions, those that serve as an opportunity to agree or object, as an incident, those 
based on public interest and benefit activities, and those made regarding limited 
data for purposes of research, public health, or health-care operation. (5) That the 
use or disclosure of limited data set (protected health information from which spe-
cific direct identifiers have been removed) for purposes of research, public health 
(i.e. to avoid a serious threat to health or safety) or health-care operation is among 
the permitted uses or disclosures without the need of the individual’s consent. (6) 
That genomic data stripped of identifiers may not be considered protected health 
information, and therefore, the use or disclosure of de-identified health informa-
tion is not restricted [US Department of Health and Human Services (28), p. 4, 
9, and 20].
(15, 22, 28, 29). In addition to HIPAA, the U.S. has the NIH secu-
rity best practices for controlled access data. This document states 
the minimum standards of National Institutes of Health (NIH) 
regarding the management and protection of controlled access to 
data transferred to and maintained by institutions either in their 
own data centers or in CCSs. The use of encryption and firewalls, 
as well as access control procedures, is suggested as protection 
mechanisms (14, 30).
Canada’s Personal Information Protection and Electronic 
Documents Act (PIPEDA) regulates the way in which members of 
the private sector collect, use, and disclose personal information17 
in commercial activities. This includes information collected and/
or stored online. According to PIPEDA, organizations or com-
panies are only allowed to use or disclose the information they 
collect on the terms agreed at the time of collection, unless a new 
expressed consent of the individual who provided that informa-
tion is obtained (22, 31–33). Similar to HIPAA, PIPEDA and the 
NIH’s best practices can encourage the use of CCSs by obligating 
CCSs providers to adopt measures that protect the safety of health 
data and the donors’ privacy.
SeLeCTeD PROJeCTS
The advancement of DNA sequencing techniques has facilitated 
and accelerated the generation of genomic data. The costs of 
sequencing have also decreased. These new conditions have 
prompted the launch of large-scale projects that involve members 
of the public and private sectors playing different roles (14). Some 
examples of PPPs that involve CCSs for genomic research include 
(1) the Collaborative Cancer Cloud that partners Intel, the Knight 
Cancer Institute at Oregon Health and Science University, the 
Dana-Faber Cancer Institute, and the Ontario Institute for Cancer 
Research; (2) the Cancer Genome Collaboratory (CGC), whose 
partners are the Open Cloud Consortium, the Ontario Institute 
for Cancer Research, and the Bionimbus Protected Data Cloud; 
(3) MSSNG that partners Autism Speaks and Google; (4) 100,000 
GP which joins Genomics England (GE) with AbbVie, Alexion 
Pharmaceuticals, AstraZeneca, Berg Health, Biogen, Dimension 
Therapeutics, GCK, Helomics, NGM Biopharmaceuticals, Roche, 
and Takeda; and (5) the ICGC that partnered with Amazon Web 
Services (AWS). We focus on the last three (Table 1).18
17 Name, age, ethnic origin, and medical records are just few of the forms of infor-
mation considered personal.
18 For more information on the first two examples, see for (1) Collaborative Cancer 
Cloud: Dana-Farber Cancer Institute and Ontario Institute for Cancer Research 
Join Collaborative Cancer Cloud | Ontario Institute for Cancer Research,” 
Ontario Institute for Cancer Research, March 31, 2016, http://oicr.on.ca/news/
news-releases/dana-farber-cancer-institute-and-ontario-institute-cancer-
research-join-collaborative-cancer-cloud; “Dana-Farber Cancer Institute and 
Ontario Institute for Cancer Research Join Collaborative Cancer Clo,” Oregon 
Health & Science University, March 31, 2016, https://news.ohsu.edu/2016/03/31/
dana-farber-cancer-institute-and-ontario-institute-for-cancer-research-join-
collaborative-cancer-cloud and for (2) Cancer Genome Collaboratory: The Cancer 
Genome Collaboratory | Genome Canada,” Genome Canada, accessed September 
7, 2016, http://www.genomecanada.ca/en/cancer-genome-collaboratory and 
“Main—Bionimbus Protected Data Cloud,” accessed September 7, 2016, https://
bionimbus-pdc.opensciencedatacloud.org/.
TabLe 1 | Summary of the selected cases.
MSSNG international Cancer Genome 
Consortium (iCGC)
100,000 Genomes Project
Launch date 2014 2008 2012
Focus Autism Cancer Rare disorders, infectious diseases, and 
common cancers
Goals To collect and sequence DNA from 
10,000 families to understand causes 
of the autism condition across its wide 
spectrum, identify its different subtypes, 
and help in the development of more 
personalized and accurate treatments
To collect and sequence 50,000 
genomes. To coordinate and generate 
current and future large-scale cancer 
genome studies in tumors from 50 
different types and subtypes of cancer 
in order to identify common patterns of 
mutation and understand the biology of 
cancer
To collect and sequence 100,000 
genomes from 75,000 patients. To 
enable new scientific discovery and 
medical insights regarding the selected 
rare disorders, infectious diseases, and 
common cancers for the creation of 
better tests, better drugs, more accurate 
and timely diagnoses and treatments, 
and more personalized care
Public and private partners Public sector: Autism Speaks-Autism 
Genetic Resource Exchange and 
Toronto’s Hospital for Sick Children
Public sector: 25 research centers from 
around the world, the TCGC, and Cancer 
Genome Collaboratory (CGC)
Public sector: Genomics England (GE), 
National Institute for Health Research, 
Public Health England, Health Education 
England, 13 National Health Services 
(NHS) Genomic Medicine Centres, GE 
Clinical Interpretation Partnership (GeCIP) 
partnership, and 85 NHS trusts and 
hospitals
Private sector: Google Private sector: Amazon Web Services 
(AWS)
Private sector: Illumina, Congenica, WuXi 
NextCODE, Omicia, Cypher Genomics, 
Nanthealth, Genomics Expert Network 
for Enterprises (GENE) Consortium, and 
GeCIP partnership
CCS provider/type Google—private company offering public 
cloud-computing services (CCSs)
AWS (Amazon)—private company 
offering public CCSs and CGC—public 
academic resource offering private CCSs
GE—company owned by the U.K. 
Department of Health offering private 
CCSs
Status/progress 7,000 whole genomes sequenced. The 
project has provided access to more than 
100 investigators from 9 countries
10,000 whole genomes sequenced 
and 89 cancer genome projects. ICGC 
Data Access Compliance Office (DACO) 
has approved access to 734 projects 
(including renewals) over the years
16,171 whole genomes sequenced. No 
mention of projects/researchers approved 
to access to the data
Characteristics of services Scalable, elastic, on-demand, and 
accessible through a broad network. 
Specialized service for big genomic data
On-demand, elastic, and scalable. 
Specialized for massive data
Scalable and elastic. Members are 
encouraged to nominate new diseases
Security and safety Encryption, online backup, and disaster 
recovery. ISO 27001, SSAE-16, SOC1, 
SOC2, and SOC3 certifications
Encryption. ISO 9001, ISO 27018, SOC1, 
SOC2, SOC3, FISMA, PCI DSS, ITAR. 
FIPS 140-2 certifications. The AWS Data 
Processing Agreement is approved by 
Art. 29 Working Group. Access approved 
by ICGC DACO
Encryption. BS7799 and ISO27001 
certifications. No raw data can be 
downloaded or withdrawn. Access 
Review Committee assesses access 
requests. GENE members pay a fee for 
access
Benefits of the specific public–
private partnership for CCSs
 1. Access to Google’s massive 
infrastructure, capabilities, 
geographical presence, and 
experience handling sensitive and 
personal data.
 2. Compliance with the laws of several 
jurisdictions.
 3. No special application or program 
needed.
 4. Enabling of global and 
multidisciplinary collaboration 
and accelerated research and 
development (R&D).
 5. No initial investment for cloud-
computing capability needed.
 6. Potential trust on the project because 
of Google’s involvement.
 7. Diverse and enriched analysis due to 
possibility to download data.
 1. Access to AWS’ massive 
infrastructure, capabilities, 
geographical presence, and 
experience handling sensitive and 
personal data.
 2. Compliance with the laws of several 
jurisdictions.
 3. No special application or program 
needed.
 4. Enabling of global and 
multidisciplinary collaboration and 
accelerated R&D.
 5. No initial investment for cloud-
computing capability needed.
 6. Potential trust on the project because 
of Amazon’s involvement.
 7. Diverse and enriched analysis due to 
possibility to download data.
 1. Private companies’ involvement 
in the data’s sequencing and the 
translational process is expected to 
accelerate the R&D process.
 2. Specially tailored for the project’s 
needs, circumstances, and UK 
regulations.
 3. GE maintains exclusive control over 
the stored data. Data cannot be 
downloaded, and they never leave the 
data center, which grants GE higher 
control over the data.
 4. Given GE’s nature (owned by U.K. 
Department of Health as opposed to 
being owned by a private company), 
participants may trust the project 
more.
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MSSNG has several partners. Autism Speaks is a non-for-
profit organization and advocacy group located in New York, U.S. 
Its involvement in MSSNG is associated with the awareness, fund 
raising, and support of basic, translational, and clinical research 
and projects such as AGRE. AGRE is a DNA repository and fam-
ily registry of genotypic and phenotypic information funded by 
Autism Speaks. The Toronto’s Sick Children Hospital is a public 
hospital located in Toronto, ON, Canada, with governmental 
funding specializing in children and affiliated to the University 
of Toronto. Its involvement in the project is on the scientific 
research area. Both parties—Autism Speaks-AGRE and Toronto’s 
Sick Children’s Hospital—represent the public sector and provide 
the genomic data, health information, and the scientific/medical 
analysis.
Google represents the private sector in MSSNG. The partner-
ship with Google outsources CCSs to store, process, and share 
the genomic data collected by Autism Speaks and Toronto’s Sick 
Children’s Hospital with researchers around the world. Google 
is a multinational company focused on Internet and computer-
related services and products whose objective is to “organize 
the world’s information and make it universally accessible and 
useful” (39). As such, it has created tools that help to organize 
almost all kind of information and fulfill its objective. For 
instance, Google’s Search, Maps, and YouTube allow users to 
access documents, images, information, videos, and roads and 
make that information useful to satisfy their individual needs. 
Google Cloud Platform supports the aforesaid services and helps 
users to do something similar with their own information. It 
also helps to store, organize, analyze, process, and make acces-
sible complete medical/health records, including genomic data. 
Google Genomics was conceived to specialize on big genomic 
data (12, 14). Furthermore, Google has long-supported the open 
source philosophy and has implemented philanthropic programs 
in areas such as climate change, public health, and poverty. In 
view of this, it would be safe to assert that one of the reasons 
MSSNG international Cancer Genome 
Consortium (iCGC)
100,000 Genomes Project
Challenges  1. Potential distrust on the project 
because of Google’s involvement.
 2. Even MSSNG having control over the 
access to the stored data, Google is 
in charge of the data’s security, safety, 
and integrity.
 3. Less control over the data, as they 
can be downloaded.
 4. Confidentiality and privacy are still 
unresolved: re-identification of 
participants is possible.
 5. Reconciliation of different expectations 
and goals of public/private sectors.
 1. Potential distrust on the project 
because of AWS’ involvement.
 2. Even ICGC having control over the 
access to the stored data, AWS is in 
charge of the data’s security, safety, 
and integrity.
 3. Less control over the data, as they 
can be downloaded.
 4. Confidentiality and privacy are still 
unresolved: re-identification of 
participants is possible.
 5. Reconciliation of different 
expectations and goals of public/
private sectors.
 1. Geographical expansion requires 
ensuring compliance with new 
jurisdictions.
 2. Large investment needed to start and 
maintain the CCS.
 3. Reduced GE’s experience handling 
massive amounts of data in 
comparison with Google’s or AWS’ 
and potential less trust on GE’s 
capacities to secure the data.
 4. Open access/open science vs. no 
download policy.
 5. Confidentiality and privacy are still 
unresolved: re-identification of 
participants is possible.
 6. Reconciliation of different expectations 
and goals of public/private sectors.
TabLe 1 | Continued
MSSNG
The project, which was launched in December 2014, is sequenc-
ing and analyzing the DNA of 10,000 families affected by autism. 
The aim of this project is to help to understand the causes of the 
condition across its wide spectrum, identify its different subtypes, 
and help in the development of more personalized and accurate 
treatments. It seeks to promote and enable open science research 
and lead to a better understanding of autism. The name of the 
project has the vowels of the word “missing” deliberately omitted 
symbolizing the missing pieces of the autism project. The project 
is a collaborative effort of Autism Speaks, Toronto’s Hospital for 
Sick Children (Centre for Applied Genomics), and Google. It 
also has funding contributions from KRG Children Charitable 
Foundation, the Canadian federal government and the province 
of Ontario, Gordon and Llura Gund Foundation, Mel Karmazin 
Foundation, and the Allerton Foundation. MSSNG’s key lead-
ers are David Glazer (Google), Mat Pletcher (Autism Speaks), 
and Stephen Scherer (Toronto’s Hospital for Sick Children and 
University of Toronto) (34, 35).
In April 2016, the project released more than 5,000 whole 
genome sequences. In August 2016, this number rose to 7,000. 
MSSNG includes 3,000 genome sequences from participants in 
the Autism Genetic Resource Exchange (AGRE) (35, 36). Until 
now, MSSNG has granted access to its database to more than 
100 investigators from 9 countries. Access to this database has 
enabled research projects on several aspects associated with 
autism. For instance, in August 2016, researchers from the 
Toronto’s Hospital for Sick Children published a study in the npj 
Genomic Medicine journal on the genome-wide characteristics 
of the novo mutation in autism and on the epigenetic risk factors 
for autism19 (38).
19 This is study is found as Yuen et al., “Genome-wide characteristics of the novo 
mutations in autism” (37), npj Genomic Medicine.
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for which Google entered this PPP with Autism Speaks and 
Toronto’s Sick Children Hospital could be its genuine interest in 
maintaining its involvement in the efficient management of big 
data and contributing to a deep understanding of autism and the 
development of personalized medicine that will help to manage 
this condition (14, 40–42).
The MSSNG database contains research data,20 whole genome 
sequencing (WGS) data, and researchers provided data (43). This 
information is stored, processed, and made available through 
Google’s infrastructure. First, the data are uploaded to Cloud 
Storage and then imported to Google Genomics. The latter allows 
researchers to access the data using Genomics APIs, explore it 
with Google BigQuery, and analyze it with Google Compute 
Engine (44).
Google’s CCSs are scalable, elastic, provided on-demand, and 
accessible through a broad network. They offer predefined or 
custom machines with persistent disks or local SSD,21 support for 
Linux and Windows, and encryption for the data on the fly before 
being transmitted. These conditions allow MSSNG to scale-up 
or scale-down as needed. Furthermore, Google’s storage service 
is highly durable with online backup and disaster recovery (45, 
46). This, along with Google’s long-term experience in IT, makes 
it the most suitable party in the PPP to be responsible for the 
CCSs of the project and for the integrity of the data. Moreover, the 
project’s nature makes its success dependent on the existence of a 
large network of researchers that contribute to the advancement 
in the understanding of autism and on the reliability and stabil-
ity of the cloud-computing infrastructure and services. Given 
Google’s global and powerful infrastructure, partnering with it 
to obtain cloud computing can enable the large global network 
of researchers that the project needs and can support a long-term 
project.
In terms of security and safety, MSSNG also seems to maintain 
a reasonable level of control over the data stored. Google’s Data 
Processing and Security Terms state that while Google processes 
the data submitted by the customer (in this case, Autism Speaks 
and Toronto’s Sick Children Hospital), it is the latter who controls 
the data. Google’s processing is only performed in accordance 
with the customer’s instructions (46, 47). Access is provided by 
Data Access Compliance Office (DACO) to anyone complying 
with the project’s access and privacy policies, which include 
the use of encrypting tools (48, 49). To ensure this, Google has 
“technical and organizational measures to protect the data against 
accidental or unlawful destruction or accidental loss or alteration, 
or unauthorized disclosure or access” in place, including several 
layers of encryption to protect the data. This includes ensuring 
that its staff complies with these measures. Google will promptly 
notify the customer of any security breach and will immediately 
20 Research data include information concerning the participants such as family 
configuration, age at time of testing, sex psychopathology, diagnosis, cognitive 
functioning, family and medical history, and other relevant clinical information, 
without including any personal identifying information.
21 A persistent disk can be attached to different virtual machines retaining the data; 
so if a virtual machine is terminated, the disk can be attached to a new one. On 
the other hand, local SSD is physically attached to the server hosting the virtual 
machine.
take the reasonable steps to minimize the harm. Google’s security 
and privacy measures comply with the ISO 27001, SSAE-16, SOC 
1, SOC 2, and SOC 3 standards (46, 50). The project’s data will 
be stored where MSSNG chooses between the U.S. or Europe or 
another location setting offered by Google (46, 51). Either Autism 
Speaks and Toronto’s Sick Children Hospital or whoever collects 
the data is responsible for obtaining the necessary consent for 
the data to be stored and processed by Google (47). Finally, all 
changes to Google’s Data Processing and Security Terms or to the 
services will be posted online (47).
iCGC and the Cancer Genome atlas 
(TCGa)
The project was launched in 2008 with the intention of coordinat-
ing and generating current and future large-scale cancer genomes 
studies in tumors from 50 different types and subtypes of cancer 
(52, 53). For this, genomes of at least 50 types of cancer will be 
collected, mapped, and shared. The objective of coordinating 
and generating numerous large-scale cancer genomes studies 
rises from the potential to identify common patterns of mutation 
and understand the biology of cancer found in using systematic 
genome-wide screens (54).
The headquarters of the project are located in the Ontario 
Institute of Cancer Research in Toronto, ON, Canada. The list 
of current ICGC members include over 25 research centers from 
Australia, Canada, China, Europe, France, Germany, India, Japan, 
Mexico, Singapore, Saudi Arabia, South Korea, Spain, the U.K., 
and U.S.22 All entities are allowed to become members, provided 
that they comply with the ICGC’s principles and guidelines (55). 
There are different types of scientific partnerships/collaborations. 
ICGC funding members of large-scale projects are expected to 
have approximately 500 patients per sample and an estimated 
contribution of USD $20 million. Those who contribute with less 
than 500 samples (at least 100) and less than USD $10 million 
are members with affiliate status. Research members are centers 
that acquire and analyze samples for one or more cancer genomes 
and that are nominated as such by a funding member, who will 
provide the necessary funds for them (52, 55).
TCGA is a collaboration between the National Cancer Institute 
and the Human Genome Research Institute to create comprehen-
sive and multidimensional maps of genomic changes in 33 types 
of cancer. TCGA is one of the world’s largest collections of cancer 
genome data available from more than 11,000 donors. TCGA 
created a pipeline to collect, select, and analyze human tissues on 
a very large scale. Its funding is federal from the National Cancer 
Institute, the NIH, and the Department of Health and Human 
Services. The project is scheduled to end in 2017 (56, 57).
There are currently 89 cancer genome projects examining 
different types of tumors. The tumors being examined are from 
the biliary tract, bladder, blood, bone, brain, breast, cervix, colon, 
eye, head and neck, kidney, liver, lung, nasopharynx, oral cavity, 
ovary, pancreas, prostate, rectum, skin, soft tissues, stomach, 
22 The NHS includes 27 institutes all of which are part of the U.S. Department of 
Health and Human Services [NIH Press (55)].
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thyroid, and uterus (55). The datasets of TCGA are also stored 
and released through AWS. The ICGC and TCGA have collected, 
stored, analyzed, and released data from 10,000 genomes. By 
2018, the ICGC project intends to have over 50,000 genomes (15, 
53, 56).
In addition to the scientific partners mentioned above, the 
project has academic and commercial partners that provide CCSs. 
The CGC is the academic partner, and AWS is the commercial 
partner in this hybrid cloud. The CGC was built and is led by the 
Ontario Institute for Cancer Research. This cloud stores data that 
are restricted to a small group of beta testers approved by ICGC 
DACO. The data stored in the CGC are provided by 25 projects 
and 14 primary sites. There are two data centers: SciNet (Toronto) 
and Bionimbus (Chicago) (58, 59). AWS hosts data obtained from 
20 projects and 12 primary sites. The datasets are hosted at the 
U.S. East (Northern Virginia) EC2 facility and are accessible in 
190 countries (54, 58–60).
Amazon is one of the world’s largest providers of CCSs. 
The services operate from several geographical regions: U.S. 
East (Northern Virginia), U.S. West (Northern California and 
Oregon), Brazil (Sao Paulo), Europe (Ireland and Frankfort), 
South Asia (Mumbai), Southeast Asia (Singapore), East Asia 
(Tokyo, Seoul, and Beijing), Australia (Sydney), and GovCloud 
(Northwestern U.S.). Canada, China, India, Ohio, and the U.K. 
have been announced for 2017. All of the data and services stay in 
their designated region. Each region has multiple separated data 
centers to prevent outages from spreading. In December 2014, 
AWS was operating 1.4 million servers. The customer chooses 
the region in which its data will be stored. ICGC chose U.S. East 
(Northern Virginia) (61–63).
The CCSs provided by AWS are on-demand, low-cost, pay-
as-you-go, and scalable. The services run in Mac, Linux, and 
Windows. Like Google, AWS has services specially tailored for 
scientific computing that adapt to the needs of massive datasets 
(60, 64, 65). AWS will notify its customers of any change to the 
services provided (63). ICGC is responsible for ensuring that the 
data comply with the respective applicable laws (66). Some of the 
AWS resources may be replaced or terminated. In these cases, 
AWS will not be held responsible for any damages, liabilities, or 
losses resulting from those replacements or terminations (66).
Amazon Web Services offers strong security measures and 
tools that have been certified and accredited, data encryption at 
rest, and in transit to manage the data. For instance, AWS security 
measures and tools have the SOC1, SOC2, SOC3, FISMA, PCI 
DSS, ISO 27018, ISO 9001, ITAR, and FIPS 140-2 certifications. 
Furthermore, the AWS Data Processing Agreement, approved by 
the Article 29 Working Group, meets the standard provisions of 
the European Commission with respect to data protection when 
data is transferred between clouds and regions. In accordance 
with the AWS privacy terms, AWS will only disclose the content 
stored in its cloud if it is mandated by law or a binding order of a 
governmental or regulatory body. AWS also offers reliable backup 
services. However, the customer, in this case ICGC, is responsible 
for the operation, maintenance, use, security, protection, and 
backup of the data. Finally, given the specialization on genomics/
health-related data, AWS expressly states that they comply with 
HIPAA (60, 62–65, 67–71).
The ICGC member nations agree to core bioethics principles 
and elements for informed consent, privacy, and access. These 
requirements include that the data and samples will be used for 
cancer research, that they will be made available to the interna-
tional research community through an open or controlled access 
database, and that this availability will be done under terms and 
conditions that will maximize the participant’s confidentiality 
(55). The data are made rapidly and freely available to the global 
research community through the ICGC data portal. Researchers 
have access to open and controlled portions of the data and to a 
number of user interfaces that address simple gene-oriented que-
ries as well as those involving genomic, clinical, and functional 
information (15, 72).
The access to the ICGC data stored and processed in the AWS 
cloud is approved by ICGC DACO, which utilizes user authen-
tication and authorization (e.g., decryption keys) to ensure safe 
access. Until today, 734 projects (including renewals) have been 
approved to have access to the ICGC data. Access to TCGA data 
is approved and done through the Cancer Genomics Cloud being 
Seven Bridges Genomics, the entity responsible for authorizing 
access to the data. This access and collaboration are expected to 
help researchers to identify commonalities and differences among 
different types of cancer. Other AWS customers/projects in the 
area of healthcare include NASA NEX, 1000 Genomes Project, 
TCGA, GenomeNext, and the Human Microbiome Project (56, 
64, 67, 73, 74).
Amazon’s official motive for entering such a partnership is its 
interest in helping to “achieve major healthcare breakthroughs 
and unlock the mysteries of the human body” through the use 
of bioinformatics. This is also one of the main reasons for them 
to develop open source tools (73). The ICGC project definitely 
benefits from the AWS’ massive infrastructure, capabilities, geo-
graphical presence, and experience in safely and efficiently han-
dling these amount of sensitive and personal data. It also benefits 
from the flexibility and adaptability of the services to the project’s 
specific needs. The cloud-computing partnerships with AWS 
and CGC allow scientists to access, search, and analyze ICGC 
without the need to install any special application or program or 
to download any of the datasets. This enhances collaboration and 
accelerates the R&D of tools and treatments for cancer patients 
(58, 60).
100,000 GP
The project, launched in late 2012, aims to “enable new scientific 
discovery and medical insights” and to “kickstart the develop-
ment of a U.K. genomics industry.” It intends to create better tests, 
better drugs, more accurate and timely diagnoses and treatments, 
and more personalized care to save lives. The project focuses on 
rare disorders, infectious diseases, and common cancers. In order 
to achieve this, the project created 13 National Health Services 
(NHS) Genomic Medicine Centres to recruit approximately 
75,000 patients to provide DNA samples and clinical information 
for the collection and analysis of 100,000 genomes between 2015 
and 2017 (75–80).
In March of 2015, patients were already being diagnosed under 
the 100,000 GP. By December 20, 2016, the project had sequenced 
16,171 genomes (81, 82).
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Genomics England is in charge of the 100,000 GP. It is a com-
pany funded in 2013 by the Department of Health. It manages the 
contracts with U.K.-based companies, universities, and hospitals 
regarding the supply of services of sequencing, data linkage, and 
analysis. GE is also responsible for the secure storage of personal 
data as per NHS rules (75).
The project’s main scientific partners are the National Institute 
for Health Research, NHS England, Public Health England, 
Health Education England, and 85 NHS trusts and hospitals 
across England (75). While GE funds the WGS for patients of 
the NHS England Genomic Medicine Centres, the Northern 
Ireland Executive and the Medical Research Council funds the 
Northern Ireland Genomic Medicine Centre. Scotland and 
Wales have recently joined the project. The company Illumina 
is the private partner responsible for sequencing the DNA in the 
Wellcome Trust Genome Campus in Hinxton, U.K. Illumina will 
also develop a platform to improve and automate genome inter-
pretation (77–79, 83). The project also partnered with other four 
companies to help with clinical interpretation: Congenica, WuXi 
NextCODE, Omicia, Cypher Genomics, and Nanthealth (79, 84).
In addition to these partnerships, the project has also partnered 
with the Genomics Expert Network for Enterprises (GENE) 
Consortium, composed of private companies, and the GE Clinical 
Interpretation Partnership (GeCIP), composed of researchers 
and clinicians from academia and the NHS researchers. There 
are currently 10 members in the GENE. Their goal is to accelerate 
the development of new diagnostics and treatments. On the other 
hand, members of the GeCIP help to interpret genomic data in a 
clinical context. Any individual, student, or staff member affiliated 
with a university or academic research institution, NHS trusts 
or authorities, charitable organization related to the 100,000 GP, 
U.K. and foreign governmental departments that carry significant 
research activity, or foreign health-care organizations (public or 
private) that undertake significant research activity can apply to 
become a member of GeCIP. Exceptionally, individuals affiliated 
with private U.K. health-care institutions, commercial compa-
nies, or self-employed can become members of GeCIP (85–88).
The raw data collected and stored by the 100,000 GPs are kept 
in GE’s data centers. In contrast to our two previous cases, no 
raw genome data can be downloaded and withdrawn from GE’s 
data center. Doctors, nurses, and health-care professionals in the 
NHS Genomic Medicine Centres have access to the data of their 
patients for health-care purposes. Researchers and companies 
need to apply to have access, but the computational analysis is 
done within its confines. The Access Review Committee assesses 
access requests by each company or researcher. Access to the data 
can only be for health research purposes, limited to the data they 
need in accordance with their application and research protocol, 
only allowed through a secure login, and as mentioned above, 
without downloading any data. Members of the GENE have to 
pay a fee for becoming members and having access to the GE data 
services. The fee for large companies (i.e., USD $1 billion market 
capitalization) is USD $320,000. The fee for smaller companies 
is USD $32,000. These fees cover part of the costs of storage, 
security, and analytic services. They also commit to having a 
specific number of employees devoted to the activities relevant 
to the project. GENE members can have a controlled access to 
up to 5,000 genomes and corresponding health information 
(78, 80, 89–91).
An independent Ethics Advisory Committee advises the 
GE board on participants’ consent, privacy, and confidentiality 
and on how to best ensure data’s security. GE will take all the 
measures necessary to maintain the security of the data. Some of 
these measures include removing identifying information from 
the raw data and encryption tools. The GE data center complies 
with the BS7799 and the ISO27001 security standards. Because 
the project is focused on England’s (and extending to Ireland’s, 
Scotland’s, and Wales’) population and the data remain in the 
GE’s data center, the project only commits to comply with U.K. 
legislation (e.g., Data Protection Act of 1998 and Access to Health 
Records Act of 1990) (77, 80, 89, 91).
The type of cloud provided by GE in this project is private, 
unlike the cloud in the MSSNG and the ICGC projects. The 
PPP differs in organization and in dynamics as well. Whereas 
in MSSNG and ICGC, the private sector was represented by the 
CCS providers, in the 100,000 GP, the CCSs are provided by 
the public sector in partnership with some private companies 
helping with the DNA sequencing and interpretation of data. 
Similar to the services provided by Google and AWS, the CCSs 
are scalable and elastic, as members can and are even encouraged 
to nominate new rare diseases and tumor types to be included 
in the project (92).
The companies’ early involvement in the research and their 
collaboration with researchers may accelerate the translation of 
basic research into concrete clinical innovative products, but the 
impact of restrictions on data downloading remain to be seen. 
Patients may have access to a better, timely, and more accurate 
diagnosis and treatment, given that any relevant information 
resulting from the sequencing and analysis of the participants’ 
samples will be returned to their doctors. Furthermore, health-
care staff is trained with new skills and practices (78, 80, 90).
The expressed intention of the parties involved in this project 
is to achieve a better understanding of the involvement of genom-
ics in cancer, rare disorders, and infectious diseases and the 
development of new diagnostic tools and personalized treatment 
that advances the field and the industry and improves patients’ 
health. This is mentioned in the project’s documents, description, 
and policies. However, their access and use model remain conten-
tious. The reason for involving members of the public and the 
private sector and for assigning them the respective roles they 
have is based on two recognitions: that the private sector has 
always had an important role in the development of innovative 
medical products and that an early involvement of all its parties 
may help to employ resources more efficiently and to accelerate 
the R&D process (77, 78, 86).
LOOKiNG FORwaRD: LeSSONS 
LeaRNeD
The three case studies presented have benefited from being PPPs. 
Google’s and AWS’ private cloud-computing infrastructure and 
services have considerably empowered the MSSNG and the 
ICGC research projects by enhancing the value of the genomic 
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and health data they have collected in the following manner. First, 
the IT companies’ infrastructure and services enable a global and 
multidisciplinary network of researchers that can collaborate and 
share their ideas, knowledge, experience, skills, and resources. 
Collaboration and sharing enhances the value of that genomic 
and health data, as more R&D can result from that data. Second, 
the global aspect of Google’s and AWS’ services (e.g., the servers 
located in different regions) requires them to comply with laws 
of several jurisdictions. This increases the possibility of expand-
ing the projects to larger geographical areas. Third, MSSNG 
and ICGC are able to use this infrastructure and these services 
without having to put up large capital investments for their setup 
and maintenance. This helps to democratize the innovation 
process, as it allows small- and medium-sized research centers 
and companies from developed and developing countries to get 
involved in such large research projects. Fourth, having Google 
and AWS as the companies responsible for providing CCS can add 
reliability and trust in the minds of the participants and the other 
partners of the projects. The reason for this potential increase 
in reliability and trust is that both companies have a long, well-
established experience in handling big data. This experience may 
translate into having the necessary resources and skills to have 
strong security measures. Furthermore, having these companies 
not only as CCS providers but also as partners in these projects 
can result in more specially tailored and better suited terms of 
service, as the companies have an invested interest in the success 
of the projects. When customers simply hire CCSs as opposed to 
forming a PPP with the companies that provide them, they usu-
ally have to adapt to the terms under which they generally provide 
their services. This is problematic given that most of these terms 
of use state limited responsibility for the integrity and mobility 
of the data. These limits are handled differently when the CCS 
providers have a larger interest invested in the project, as in the 
case of MSSNG and ICGC.
Some of the benefits found in these two cases are also observed 
in the 100,000 GP, including, above all, links to health-care data 
in a network of researchers and innovators who share their ideas, 
knowledge, experience, skills, and resources, thereby increas-
ing the value of the genomic data and the potential of a more 
efficient R&D process. However, given that in this case, the CCSs 
are provided by a private in-house data center, there are certain 
differences. For instance, the 100,000 GP only complies with the 
laws of the U.K. This makes it difficult to expand the project to 
other regions. Second, this project had to make a considerable 
initial capital investment to set up the data center and the cloud-
computing infrastructure. Third, contrary to MSSNG and ICGC, 
the 100,000 GP maintains exclusive control over the data. This 
could increase the trust that users and participants may have on 
the protection of their privacy but decrease access and use for 
research and downstream benefits for patients. Moreover, given 
the limited experience that GE has in comparison with Google 
or AWS in handling massive amounts of data, some participants 
may in fact doubt GE’s capacity to effectively protect the donors’ 
data. Yet, the participation of the private sector in the sequencing 
and translational process in this project is expected to acceler-
ate the R&D process, as they bring in their infrastructure and 
their scientific, technological, and budgetary experience into the 
process. Furthermore, having such an early involvement of private 
companies in the research process allows all parties to share their 
expectations and to contribute their opinions and their interests 
(e.g., nominating new rare diseases) to the general coordination 
and management of the partnerships challenges.
Overall, it could be said that while being organized as PPPs 
and employing CCSs, the three projects have advanced quickly 
and are organizing themselves to be important sources of future 
personalized medicine. Nevertheless, the benefits and achieve-
ments that the three projects have had, there still are unresolved 
matters. The first is the protection of confidentiality and privacy. 
The three projects implement, to the best of their abilities, security 
measures (e.g., encryption, removal of identifying information, 
controlled access, privacy and data sharing policies, etc.) that aim 
to maintain the confidentiality and privacy of the participants. 
The 100,000 GP even provides that the data will never leave 
their data center, which may undermine further research and 
innovation. In all the three, however, the re-identification of 
the participants remains a possibility due to the necessary link-
age with health records. The second concern is the differences 
in expectations and goals that the different partners may have 
while joining and participating in a project. In the MSSNG and 
the ICGC projects, the stated reasons for Google and AWS to 
become partners do not seem to contradict the incentives of the 
partners of the public sector, namely, to advance the understand-
ing of genetic diseases and to improve patients’ health with better 
diagnostics and personalized treatments. However, there may 
be other untold goals. For example, advertising is the source of 
the majority of Google’s revenues (93). Furthermore, Google 
is deeply involved in the development of artificial intelligence 
(94, 95). Given Google’s other possible interests, it is important 
that projects develop robust and transparent governance struc-
tures and conflict of interest policies to secure public trust. On 
the other hand, in the 100,000 GP, its private partners have a 
strong economic expectation/incentive that may run contrary 
to the scientific/medical goals. It should be stated, however, that 
this may also occur later on in the MSSNG and ICGC projects 
when the projects enter the translational phase. The third issue 
is the possible loss of control of the data, particularly in the case 
of the MSSNG and the ICGC projects that allow downloading of 
data for more diverse and enriched analysis. While the data are 
stored and analyzed in data centers with strong security measures 
and while they grant MSSNG and ICGC control over their data, 
neither of the leading institutions in these projects is in charge 
of the management, implementation, and decision-making 
regarding the security measures. Finally, as regards the 100,000 
GP and its private data center, the fact that the data never leave 
the data center causes underutilization of the project’s data. This 
characteristic may also be perceived as in conflict with some of 
the common principles of open science (e.g., open data sharing, 
fast dissemination of knowledge, cumulative R&D, etc.) (96), as 
any data sharing will be very limited.
An important issue in our analysis of all the three cases is 
that we could not confirm whether some of the suggestions to 
overcome challenges found in PPPs that we mentioned earlier are 
actually being implemented, as our sources of information were 
mute in this respect.
13
Granados Moreno et al. PPP, Cloud Computing, and Genomics 
Frontiers in Medicine | www.frontiersin.org January 2017 | Volume 4 | Article 3
CONCLUSiON
Public–private partnership is a useful and effective collaborative 
R&D model. It is particularly relevant for projects where the R&D 
process cannot be fully taken on by the public or the private sector 
alone. PPPs enable members of both sectors to come together 
and increase the availability of multiple resources and diverse 
knowledge and expertise that can make the innovation process 
less burdensome and costly, more efficient, effective, shorter, and 
with a wider reach. It also makes the R&D process more efficient, 
as it allows objectives and needs of the parties involved in the 
different stages of the R&D process to be known and addressed. 
In this respect, particularly in genomic research, the model of 
PPP facilitates the translation of basic to clinical research and it 
enables the use of CCSs.
Cloud-computing services increase the usefulness of 
genomic data for understanding disorders with a genetic 
component and developing improved and more personalized 
diagnostic tools, drugs, and treatments. They achieve this by 
enlarging the data users’ network in two ways. They can extend 
the geographical availability of the genomic data they store. 
They make it easier and cheaper for all users to access, analyze, 
and store their own and others’ data, regardless of whether 
they are or belong to small- and medium-sized centers from 
developed or developing countries. As a result, there has been 
an increase in the use of CCSs in health-care services and 
health-care research.
The three projects we discussed in this article benefit from 
the PPP model as well as from the use of CCSs, despite the 
differences in the way they are organized. However, there are 
two important matters that should be kept in mind. First, pro-
tection of data and privacy is essential for cloud computing 
to fully benefit and spur medical and genomic research. End-
users are likely to have more trust in CCSs when they perceive 
that their data and privacy are properly protected. The more 
trust end-users have in the cloud, the bigger the network of 
users and projects using the data in the cloud will be. The 
larger the network of contributors, the faster the progression 
in genomic and medical research could happen and the more 
chances that patients will have to benefit from personalized 
healthcare (22). Second, even though the benefits of PPPs 
are palpable, this collaborative model still presents certain 
challenges. Large-scale genomic projects can be of long dura-
tion and cover a sizable geographical area. They can include 
a variety of partners and contributors with different and 
potentially conflicting objectives, resources, expectations, 
and viewpoints. Early integration of all parties, timely and 
appropriate distribution of functions and responsibilities, 
frequent monitoring of results, constant communication 
and trust among the partners, and adequate governance 
frameworks are helpful in managing those complications and 
increasing the chances of a successful PPP, provided also that 
the public is kept involved and informed about the project 
(3, 4).
Learning from the experience of past PPPs is critical in order to 
avoid making the same mistakes in the future. Therefore, research 
on those past PPPs to document the projects’ achievements and 
failures as well as to provide information on the development 
and outputs of such partnerships would provide helpful guidance 
for future PPPs (3, 7). In addition, we propose that guidelines 
on best practices to adequately manage personal information 
stored in clouds and transferred online for research purposes be 
established to foster the protection of data integrity and privacy. 
These guidelines should enable research institutions to maintain 
control over the use of the data during and after research projects 
conclude and encourage data transfer in accordance with open 
science principles.
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